PL2654897T3 - Sposób zwiększania tempa implantacji zarodka w macicy matki u ssaków, zastosowanie skutecznej ilości lektyny wiążącej betagalaktozyd lub jej pochodnych, lektyna wiążąca betagalaktozyd lub pochodne i produkt - Google Patents

Sposób zwiększania tempa implantacji zarodka w macicy matki u ssaków, zastosowanie skutecznej ilości lektyny wiążącej betagalaktozyd lub jej pochodnych, lektyna wiążąca betagalaktozyd lub pochodne i produkt

Info

Publication number
PL2654897T3
PL2654897T3 PL11805370T PL11805370T PL2654897T3 PL 2654897 T3 PL2654897 T3 PL 2654897T3 PL 11805370 T PL11805370 T PL 11805370T PL 11805370 T PL11805370 T PL 11805370T PL 2654897 T3 PL2654897 T3 PL 2654897T3
Authority
PL
Poland
Prior art keywords
galactoside
beta
derivatives
binding lectin
uterus
Prior art date
Application number
PL11805370T
Other languages
English (en)
Inventor
Marcelo Dias Baruffi
Erika DA SILVA CARVALHO MORANI
Marcelo RONCOLETTA
Camillo del Cistia ANDRADE
Lílian CATALDI RODRIGUES
Original Assignee
Inprenha Biotecnologia e Desenvolvimento Avançado S.A.
Universidade De São Paulo - Usp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inprenha Biotecnologia e Desenvolvimento Avançado S.A., Universidade De São Paulo - Usp filed Critical Inprenha Biotecnologia e Desenvolvimento Avançado S.A.
Publication of PL2654897T3 publication Critical patent/PL2654897T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1732—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/178—Lectin superfamily, e.g. selectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PL11805370T 2010-12-21 2011-12-09 Sposób zwiększania tempa implantacji zarodka w macicy matki u ssaków, zastosowanie skutecznej ilości lektyny wiążącej betagalaktozyd lub jej pochodnych, lektyna wiążąca betagalaktozyd lub pochodne i produkt PL2654897T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BRPI1005702A BRPI1005702B1 (pt) 2010-12-21 2010-12-21 método para aumentar a taxa de implantação de embriões no útero materno em mamíferos, uso de uma quantidade eficaz de uma lectina ligante de beta-galactosídeo ou derivados da mesma e produto
PCT/BR2011/000454 WO2012083396A1 (en) 2010-12-21 2011-12-09 Method for increasing embryo implantation rate in mother's uterus in mammals, use of an effective amount of beta - galactoside - binding lectin or derivatives thereof, beta - galactoside - binding lectin or derivatives and product.
EP11805370.1A EP2654897B1 (en) 2010-12-21 2011-12-09 Method for increasing embryo implantation rate in mother's uterus in mammals, use of an effective amount of beta-galactoside-binding lectin or derivatives thereof, beta-galactoside-binding lectin or derivatives and product

Publications (1)

Publication Number Publication Date
PL2654897T3 true PL2654897T3 (pl) 2020-05-18

Family

ID=45463120

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11805370T PL2654897T3 (pl) 2010-12-21 2011-12-09 Sposób zwiększania tempa implantacji zarodka w macicy matki u ssaków, zastosowanie skutecznej ilości lektyny wiążącej betagalaktozyd lub jej pochodnych, lektyna wiążąca betagalaktozyd lub pochodne i produkt

Country Status (11)

Country Link
US (1) US9637533B2 (pl)
EP (2) EP3623008A1 (pl)
JP (3) JP6120374B2 (pl)
CN (2) CN109966474A (pl)
BR (1) BRPI1005702B1 (pl)
ES (1) ES2756773T3 (pl)
PL (1) PL2654897T3 (pl)
PT (1) PT2654897T (pl)
RU (1) RU2631598C2 (pl)
WO (1) WO2012083396A1 (pl)
ZA (1) ZA201304626B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1005702B1 (pt) 2010-12-21 2020-02-04 Inprenha Biotecnologia E Desenvolvimento Avancado Ltda Me método para aumentar a taxa de implantação de embriões no útero materno em mamíferos, uso de uma quantidade eficaz de uma lectina ligante de beta-galactosídeo ou derivados da mesma e produto
CA3059055C (en) * 2017-01-15 2023-03-07 Arex Life Sciences, Llc Methods for improving fertility in artificial insemination
WO2021086983A1 (en) 2019-10-29 2021-05-06 TMRW Life Sciences, Inc. Apparatus to facilitate transfer of biological specimens stored at cryogenic conditions
US11817187B2 (en) * 2020-05-18 2023-11-14 TMRW Life Sciences, Inc. Handling and tracking of biological specimens for cryogenic storage
CN111658223A (zh) * 2020-06-11 2020-09-15 上海滔华生物医药科技合伙企业（有限合伙） 一种受体牛的筛选方法
JP7610303B2 (ja) 2020-09-24 2025-01-08 ティーエムアールダブリュ ライフサイエンシーズ，インコーポレイテツド 極低温条件で保管された生物学的試料の移送を容易にするためのワークステーション及び装置
WO2022066192A1 (en) 2020-09-24 2022-03-31 TMRW Life Sciences, Inc. Cryogenic storage system with sensors to measure one or more parameters therewithin
CA3192431A1 (en) 2020-10-02 2022-04-07 Brian Joseph Bixon Interrogation device and/or system having alignment feature(s) for wireless transponder tagged specimen containers and/or carriers
CA3200508A1 (en) 2020-12-10 2022-06-16 TMRW Life Sciences, Inc. Specimen holder with wireless transponder for attachment to specimen collection body
AU2022207973B2 (en) 2021-01-13 2024-06-27 Tmrw Life Sciences, Llc Systems, apparatus and methods to pick and/or place specimen containers
US12527318B2 (en) 2021-10-08 2026-01-20 TMRW Life Sciences, Inc. Systems, apparatus and methods to pick and/or place specimen containers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869081A (en) * 1996-06-28 1999-02-09 The Population Council Progesterone vaginal ring for treatment of infertility
AU2707100A (en) * 1998-11-30 2000-06-19 Ivf Sciences Colorado, Inc. System and sequential culture media for in vitro fertilization
AU2000228211A1 (en) * 2000-03-09 2001-09-17 Yves Chicheportiche A method for increasing the in vitro production of cystic embryoid bodies from mammalian embryonic stem cells
RU2272630C2 (ru) * 2004-04-28 2006-03-27 ФГОУ ВПО "Курская государственная сельскохозяйственная академия им. проф. И.И. Иванова" Способ повышения выживаемости эмбрионов у коров
US20070185014A1 (en) * 2006-02-09 2007-08-09 The Schepens Eye Research Institute, Inc. Methods and compositions for modulating conjunctival goblet cells
EP1908476A1 (en) 2006-09-28 2008-04-09 Charite-Universitätsmedizin Berlin Galectin-2 for the treatment of inflammatory diseases of the skin
US20120177996A1 (en) * 2010-10-21 2012-07-12 Eastman Chemical Company Nonwoven article with ribbon fibers
BRPI1005702B1 (pt) 2010-12-21 2020-02-04 Inprenha Biotecnologia E Desenvolvimento Avancado Ltda Me método para aumentar a taxa de implantação de embriões no útero materno em mamíferos, uso de uma quantidade eficaz de uma lectina ligante de beta-galactosídeo ou derivados da mesma e produto

Also Published As

Publication number Publication date
US9637533B2 (en) 2017-05-02
JP2017081976A (ja) 2017-05-18
CN109966474A (zh) 2019-07-05
EP2654897B1 (en) 2019-08-21
JP6673998B2 (ja) 2020-04-01
ES2756773T3 (es) 2020-04-27
JP2019023208A (ja) 2019-02-14
CN103702720B (zh) 2020-07-07
ZA201304626B (en) 2014-09-25
CN103702720A (zh) 2014-04-02
RU2631598C2 (ru) 2017-09-25
EP3623008A1 (en) 2020-03-18
EP2654897A1 (en) 2013-10-30
JP2014500279A (ja) 2014-01-09
BRPI1005702B1 (pt) 2020-02-04
PT2654897T (pt) 2019-12-02
BRPI1005702A2 (pt) 2013-04-02
RU2013133832A (ru) 2015-01-27
US20140057858A1 (en) 2014-02-27
JP6120374B2 (ja) 2017-04-26
WO2012083396A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
PT2654897T (pt) Método para aumentar a taxa de implantação de embriões no útero da progenitora em mamíferos, utilização de uma quantidade eficaz de lectina de ligação a beta-galactósido ou seus derivados, lectina de ligação a beta-galactósido ou derivados e produto
IL215842A0 (en) Intrauterine system for use in medical treatment
IL221160A (en) 4,2,1-triazine-3-amine derivatives, a process for their preparation and use for drug preparation
PH12013500892A1 (en) Composition for use in the prevention and/or treatment of skin conditions and skin diseases
IL244293A0 (en) Pharmaceutical preparation and method of treatment for emergency contraception
PH12013500876A1 (en) Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases
IL236123A0 (en) Preparations containing n-[4,2-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-4,1-dihydro-4-oxoquinoline-3-carboxamide for use in the treatment of cftr-mediated disorders
ZA201403596B (en) Composition for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease
IL216967A0 (en) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases
EP2565289A4 (en) An amorphous alloy die casting and the thermal treatment process thereof
IL225793A0 (en) Methods and preparations for curing insulin-related medical conditions
HUE044715T2 (hu) siRNS és felhasználása eljárásokban és kompozíciókban szembajok kezelésére és/vagy megelõzésére
EP2709632A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES
IL261269A (en) Pharmaceutical preparations containing 7-(h1-imidazol-4-ylmethyl)-8,7,6,5-tetrahydro-quinoline for the treatment of skin diseases and conditions
IL235410A0 (en) A dental implant system with an oval plate and its components
WO2010085799A9 (en) Compositions and method for the treatment of parkinson's disease
IL222482A0 (en) Methods and compositions for the treatment of fluid accumulation in and/or under the retina
EP2835191A4 (en) CONTINUOUS CASTING MOLD FROM A TITANIUM OR TITANIUM ALLOY BLOCK AND CONTINUOUS CASTING DEVICE THEREWITH
IT1400089B1 (it) Composizione in polvere per la prevenzione e il trattamento delle patologie podali degli animali
IT1396725B1 (it) Metodo per prolungare e migliorare la funzionalita' di spermatozoi in vitro.
SG10201501606VA (en) Compounds, compositions, formulations and their uses in the treatment of diseases related to copper retention or hepatic disorders
IL235095A0 (en) Intrauterine application of 18-methyl-15 in cell, 16 in cell-methylene-19-nor-20-spirox-4-en-3-one systems, intrauterine systems containing 18-methyl-15 in cell, 16 in cell-methylene- 19-nor-20-spirox-4-en-3-one and their use in contraception and gynecological treatment
IL222642A0 (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
IL243237A0 (en) Methods and preparations for the treatment of fluid accumulation in and/or under the retina
EP2789332A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING DIAMINODIPHENYLSULFONE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH BONE MASS REDUCTION